• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

作者信息

Jeste D V, Caligiuri M P, Paulsen J S, Heaton R K, Lacro J P, Harris M J, Bailey A, Fell R L, McAdams L A

机构信息

Department of Psychiatry, University of California, San Diego, USA.

出版信息

Arch Gen Psychiatry. 1995 Sep;52(9):756-65. doi: 10.1001/archpsyc.1995.03950210050010.

DOI:10.1001/archpsyc.1995.03950210050010
PMID:7654127
Abstract

BACKGROUND

Neuroleptic-induced tardive dyskinesia (TD) is a major iatrogenic disorder that is more prevalent among older patients. The objective of this study was to determine the incidence of and risk factors for TD in neuroleptic-treated patients over age 45 years.

METHODS

We studied 266 middle-aged and elderly outpatients with a median duration of 21 days of total lifetime neuroleptic exposure at study entry. Most patients were treated throughout the study with either a high-potency or a low-potency neuroleptic and maintained on relatively low doses. The patients were followed up at 1- to 3-month intervals with "blind" assessment of psychopathologic condition, clinically as well as instrumentally (ie, using electromechanical sensors with computerized data reduction, including spectral analysis) evaluated movement disorder, and global cognitive function.

RESULTS

Cumulative incidence of TD was 26%, 52%, and 60% after 1, 2, and 3 years, respectively. The principal risk factors for TD were duration of prior neuroleptic use at baseline, cumulative amount of high-potency neuroleptics, history of alcohol abuse/dependence, borderline or minimal dyskinesia, and tremor on instrumental assessment.

CONCLUSION

Use of higher amounts of neuroleptics, particularly high-potency ones, should be avoided in older patients, patients with alcohol abuse/dependence, or patients with a subtle movement disorder at baseline; these patients are at a higher risk of developing TD.

摘要

相似文献

1
Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
Arch Gen Psychiatry. 1995 Sep;52(9):756-65. doi: 10.1001/archpsyc.1995.03950210050010.
2
Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.确定长期使用抗精神病药物的门诊患者中迟发性运动障碍的风险因素。耶鲁迟发性运动障碍研究的结果。
Arch Gen Psychiatry. 1993 Sep;50(9):723-33. doi: 10.1001/archpsyc.1993.01820210057007.
3
Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.老年患者使用典型抗精神病药物低剂量治疗早期迟发性运动障碍的发生率。
Am J Psychiatry. 1999 Feb;156(2):309-11. doi: 10.1176/ajp.156.2.309.
4
Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.预测长期服用抗精神病药物门诊患者迟发性运动障碍的风险
J Clin Psychiatry. 1993 Apr;54(4):133-9.
5
Changing epidemiology of tardive dyskinesia: an overview.迟发性运动障碍的流行病学变化:概述
Am J Psychiatry. 1981 Mar;138(3):297-309. doi: 10.1176/ajp.138.3.297.
6
Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.
J Am Geriatr Soc. 1999 Jun;47(6):716-9. doi: 10.1111/j.1532-5415.1999.tb01595.x.
7
Prospective study of tardive dyskinesia in the elderly: rates and risk factors.老年人迟发性运动障碍的前瞻性研究:发生率及风险因素。
Am J Psychiatry. 1998 Nov;155(11):1521-8. doi: 10.1176/ajp.155.11.1521.
8
High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.
Psychopharmacol Bull. 1992;28(1):87-92.
9
Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life.
Arch Gen Psychiatry. 1995 Jun;52(6):478-86. doi: 10.1001/archpsyc.1995.03950180064009.
10
The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.抗精神病药物治疗的糖尿病患者中迟发性运动障碍的患病率。一项对照研究。
Arch Gen Psychiatry. 1991 Mar;48(3):259-63. doi: 10.1001/archpsyc.1991.01810270071010.

引用本文的文献

1
Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings.真实世界索赔分析以描述长期护理环境中迟发性运动障碍的负担
Neurol Ther. 2025 Sep 4. doi: 10.1007/s40120-025-00820-z.
2
Treatable Hyperkinetic Movement Disorders Not to Be Missed.不可漏诊的可治疗性运动亢进性疾病
Front Neurol. 2021 Dec 1;12:659805. doi: 10.3389/fneur.2021.659805. eCollection 2021.
3
Assesment of Risk Factors for Tardive Dyskinesia.评估迟发性运动障碍的风险因素。
Psychopharmacol Bull. 2020 Jul 23;50(3):36-46.
4
Management of Tardive Syndrome: Medications and Surgical Treatments.迟发性运动障碍的治疗:药物治疗和手术治疗。
Neurotherapeutics. 2020 Oct;17(4):1694-1712. doi: 10.1007/s13311-020-00898-3.
5
The effects of valbenazine on tardive dyskinesia in older and younger patients.盐酸胍法辛对老年和年轻患者迟发性运动障碍的影响。
Int J Geriatr Psychiatry. 2020 Jan;35(1):69-79. doi: 10.1002/gps.5218. Epub 2019 Oct 31.
6
Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study.迟发性运动障碍精神科住院患者的危险因素及结局分析:一项全国性病例对照研究。
Heliyon. 2019 May 17;5(5):e01745. doi: 10.1016/j.heliyon.2019.e01745. eCollection 2019 May.
7
Segmental Dystonia in the Context of Dextromethorphan Abuse: A New Cause of Delayed Onset Drug-Induced Dystonia?右美沙芬滥用背景下的节段性肌张力障碍:迟发性药物性肌张力障碍的一个新病因?
Mov Disord Clin Pract. 2015 Mar 28;2(3):299-300. doi: 10.1002/mdc3.12148. eCollection 2015 Sep.
8
[Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].[抗精神病药物所致精神分裂症性精神病的运动症状 - 第3部分:迟发性运动障碍]
Nervenarzt. 2019 May;90(5):472-484. doi: 10.1007/s00115-018-0629-7.
9
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.VMAT-2抑制剂治疗迟发性运动障碍:随机对照试验的系统评价和荟萃分析
Drug Des Devel Ther. 2018 May 14;12:1215-1238. doi: 10.2147/DDDT.S133205. eCollection 2018.
10
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.迟发性运动障碍的治疗:概述及重点关注囊泡单胺转运体 2 抑制剂。
Drugs. 2018 Apr;78(5):525-541. doi: 10.1007/s40265-018-0874-x.